RNA THERAPEUTICS INC.
mRNA-based vaccines formulated in lipid nanoparticles for infectious diseases, initially targeting pan-COVID-19 protection
- Sector
- Biotech
- Total capital
- $300K
- Federal grants
- $300K
- 1 award · 2024
- Rank in peer group#52 of 392
- Private capital raised
- None on recordNo Form D filings on SEC EDGAR. Some raises are not filed.
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 0
- 40 pending
Capital timeline
Latest events
- Federal grantHealth and Human S · Phase I · Development of a Pan-COVID-19 Vaccine Candidate$300K
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Standing among 392 peers
Line = medianBiotech · Molecule
- Federal grants#52 · top 13%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
No founders are linked to this company yet.
Founders appear once a person is matched to the company through its own patents, grants or filings. We never infer people from social profiles.
Checked: USPTO inventors; federal award principal investigators; SEC Form D related persons · Oct 23, 2026
Claim this profile to add your teamWhat it has protected
USPTO · 0 granted of 40- PendingSingle-chain Zagotenemab Antibody-transferrin Fusion Protein For Enhanced Efficacy And IndicationsUSPTOApplication 18886969
- PendingSingle-chain MEDI1341 Antibody-transferrin Fusion Protein For Enhanced Efficacy And IndicationsUSPTOApplication 18886978
- PendingSingle-chain Ustekinumab Antibody-transferrin Fusion Protein For Enhanced Efficacy And IndicationsUSPTOApplication 18882532
Show all 40 patent records
- Single-chain Zagotenemab Antibody-transferrin Fusion Protein For Enhanced Efficacy And IndicationsMar 19, 2026 · Application 18886969Pending
- Single-chain MEDI1341 Antibody-transferrin Fusion Protein For Enhanced Efficacy And IndicationsMar 19, 2026 · Application 18886978Pending
- Single-chain Ustekinumab Antibody-transferrin Fusion Protein For Enhanced Efficacy And IndicationsMar 12, 2026 · Application 18882532Pending
- Single-chain Trastuzumab Antibody-transferrin Fusion Protein For Enhanced Efficacy And IndicationsMar 12, 2026 · Application 18830561Pending
- Single-chain Tilavonemab Antibody-transferrin Fusion Protein For Enhanced Efficacy And IndicationsMar 5, 2026 · Application 18822148Pending
- Single-chain Tildrakizumab Antibody-transferrin Fusion Protein For Enhanced Efficacy And IndicationsMar 5, 2026 · Application 18822154Pending
- Single-chain Teprotumumab Antibody-transferrin Fusion Protein For Enhanced Efficacy And IndicationsMar 5, 2026 · Application 18821955Pending
- Single-chain Solanezumab Antibody-transferrin Fusion Protein For Enhanced Efficacy And IndicationsMar 5, 2026 · Application 18821862Pending
- Single-chain Semorinemab Antibody-transferrin Fusion Protein For Enhanced Efficacy And IndicationsFeb 26, 2026 · Application 18815737Pending
- Single-chain Secukinumab Antibody-transferrin Fusion Protein For Enhanced Efficacy And IndicationsFeb 26, 2026 · Application 18814492Pending
- Single-chain Romosozumab Antibody-transferrin Fusion Protein For Enhanced Efficacy And IndicationsFeb 26, 2026 · Application 18814490Pending
- Single-chain Risankizumab Antibody-transferrin Fusion Protein For Enhanced Efficacy And IndicationsFeb 26, 2026 · Application 18812880Pending
- Single-chain Romiplostim Antibody-transferrin Fusion Protein For Enhanced Efficacy And IndicationsFeb 26, 2026 · Application 18812982Pending
- Single-chain Ravulizumab Antibody-transferrin Fusion Protein For Enhanced Efficacy And IndicationsFeb 26, 2026 · Application 18811717Pending
- Single-chain Ranibizumab Antibody-transferrin Fusion Protein For Enhanced Efficacy And IndicationsFeb 19, 2026 · Application 18809181Pending
- Single-chain Prasinezumab Antibody-transferrin Fusion Protein For Enhanced Efficacy And IndicationsFeb 19, 2026 · Application 18807943Pending
- Single-chain Ocrelizumab Antibody-transferrin Fusion Protein For Enhanced Efficacy And IndicationsFeb 19, 2026 · Application 18805486Pending
- Single-chain Ofatumumab Antibody-transferrin Fusion Protein For Enhanced Efficacy And IndicationsFeb 19, 2026 · Application 18805506Pending
- Single-chain Natalizumab Antibody-transferrin Fusion Protein For Enhanced Efficacy And IndicationsFeb 19, 2026 · Application 18803347Pending
- Single-chain Lecanemab Antibody-transferrin Fusion Protein For Enhanced Efficacy And IndicationsFeb 19, 2026 · Application 18803103Pending
- Single-chain Infliximab Antibody-transferrin Fusion Protein For Enhanced Efficacy And IndicationsFeb 12, 2026 · Application 18801147Pending
- Single-chain Ixekizumab Antibody-transferrin Fusion Protein For Enhanced Efficacy And IndicationsFeb 12, 2026 · Application 18801197Pending
- Single-chain Gosuranemab Antibody-transferrin Fusion Protein For Enhanced Efficacy And IndicationsFeb 12, 2026 · Application 18800035Pending
- Single-chain Guselkumab Antibody-transferrin Fusion Protein For Enhanced Efficacy And IndicationsFeb 12, 2026 · Application 18800039Pending
- Single-chain Gantenerumab Antibody-transferrin Fusion Protein For Enhanced Efficacy And IndicationsFeb 12, 2026 · Application 18800034Pending
- Single-chain Exidavnemab Antibody-transferrin Fusion Protein For Enhanced Efficacy And IndicationsFeb 12, 2026 · Application 18798688Pending
- Single-chain Eculizumab Antibody-transferrin Fusion Protein For Enhanced Efficacy And IndicationsFeb 12, 2026 · Application 18796212Pending
- Single-chain Dupilumab Antibody-transferrin Fusion Protein For Enhanced Efficacy And IndicationsFeb 12, 2026 · Application 18796151Pending
- Single-chain Donanemab Antibody-transferrin Fusion Protein For Enhanced Efficacy And IndicationsFeb 5, 2026 · Application 18795122Pending
- Single-chain Crenezumab Antibody-transferrin Fusion Protein For Enhanced Efficacy And IndicationsFeb 5, 2026 · Application 18793837Pending
- Single-chain Cetuximab Antibody-transferrin Fusion Protein For Enhanced Efficacy And IndicationsFeb 5, 2026 · Application 18792501Pending
- Single-chain Cinpanemab Antibody-transferrin Fusion Protein For Enhanced Efficacy And IndicationsFeb 5, 2026 · Application 18792521Pending
- Single-chain Canakinumab Antibody-transferrin Fusion Protein For Enhanced Efficacy And IndicationsFeb 5, 2026 · Application 18791419Pending
- Single-chain Brolucizumab Antibody-transferrin Fusion Protein For Enhanced Efficacy And IndicationsFeb 5, 2026 · Application 18791404Pending
- Single-chain Bevacizumab Antibody-transferrin Fusion Protein For Enhanced Efficacy And IndicationsFeb 5, 2026 · Application 18789439Pending
- Single-chain Belimumab Antibody-transferrin Fusion Protein For Enhanced Efficacy And IndicationsJan 29, 2026 · Application 18788021Pending
- Single-chain Aflibercept Antibody-transferrin Fusion Protein For Enhanced Efficacy And IndicationsJan 29, 2026 · Application 18786456Pending
- Single-chain Alemtuzumab Antibody-transferrin Fusion Protein For Enhanced Efficacy And IndicationsJan 29, 2026 · Application 18786461Pending
- Single-chain Basiliximab Antibody-transferrin Fusion Protein For Enhanced Efficacy And IndicationsJan 29, 2026 · Application 18786478Pending
- Single-chain Aducanumab Antibody-transferrin Fusion Protein For Enhanced Efficacy And IndicationsJan 22, 2026 · Application 18780444Pending
Related companies, and why
- Comanche BiopharmaSimilar federal contract value in Biotech · null in contracts
- Expansion TherapeuticsSimilar federal contract value in Biotech · null in contracts
- Atsena Therapeutics, Inc.Similar federal contract value in Biotech · null in contracts
- SepternaSimilar federal contract value in Biotech · null in contracts
- APERTURE THERAPEUTICS, INC.Similar federal contract value in Biotech · null in contracts
- ABEOME CORPORATIONSimilar federal contract value in Biotech · null in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .